New developments in Australian regenerative medicine

10 December 2010

A possible refocus on basic stem cell research to the exclusion of the development of clinical interventions is an interesting move from the Australian government, in contrast to the new trend towards clinical trials of stem cell therapeutics (see previous news). Possibly their hope is that the commercial sector will fill this gap; this week Australian company Mesoblast Ltd announced a staggering $2 billion agreement with US company Cephalon to develop adult stem cell therapies.


More from us

Genomics and policy news